High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers

Gastric Cancer

Volumn 17, Issue 3, 2014, Pages 442-449

  Fassan, Matteo ^a   Simbolo, Michele ^a   Bria, Emilio ^b   Mafficini, Andrea ^a   Pilotto, Sara ^b   Capelli, Paola ^a   Bencivenga, Maria ^c   Pecori, Sara ^a   Luchini, Claudio ^a   Neves, Diogo ^a   Turri, Giona ^a   Vicentini, Caterina ^a   Montagna, Licia ^a   Tomezzoli, Anna ^a   Tortora, Giampaolo ^b   Chilosi, Marco ^a   De Manzoni, Giovanni ^c   Scarpa, Aldo ^a  

^a Department of Pathology and Diagnostics ARC NET Research Centre University and Hospital Trust of Verona ^*  (Italy)

^b Hospital and University Trust   (Italy)

^c University/General Hospital of Verona   (Italy)

Author keywords

Biomarkers; Early gastric cancer; Gastric carcinogenesis; Intraepithelial neoplasia; Next generation sequencing

Indexed keywords

ADULT; AGED; APC GENE; ARTICLE; ATM GENE; CDKN2A GENE; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY CANCER; FEMALE; FGFR3 GENE; GASTRIC INTRAEPITHELIAL NEOPLASIA; GENE AMPLIFICATION; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; IDH2 GENE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MET GENE; MIDDLE AGED; MUTATIONAL ANALYSIS; ONCOGENE; PHENOTYPE; PIK3CA GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RB1 GENE; RET GENE; RETROSPECTIVE STUDY; SOMATIC MUTATION; STK11 GENE; STOMACH CANCER; TP53 GENE; ADENOCARCINOMA; BIOPSY; CARCINOMA IN SITU; DISEASE COURSE; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PATHOLOGY; PRECANCEROUS CONDITIONS; PROCEDURES; STOMACH NEOPLASMS; TUMOR INVASION;

PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; BIOPSY; CARCINOMA IN SITU; DISEASE PROGRESSION; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84903713331     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-013-0315-1     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Correa P. Gastric cancer: overview. Gastroenterol Clin N Am. 2013;42:211-7.
3. Rugge M, Pennelli G, Pilozzi E, Fassan M, Ingravallo G, Russo VM, et al. Gastritis: the histology report. Dig Liver Dis. 2011;43(suppl 4):S373-84.
4. Fassan M, Baffa R, Kiss A. Advanced precancerous lesions within the GI tract: the molecular background. Best Pract Res Clin Gastroenterol. 2013;27:159-69.
5. Fassan M, Croce CM, Rugge M. miRNAs in precancerous lesions of the gastrointestinal tract. World J Gastroenterol. 2011;17:5231-9.
6. Rugge M, Fassan M, Graham DY. Clinical guidelines: secondary prevention of gastric cancer. Nat Rev Gastroenterol Hepatol. 2012;9:128-9.
7. Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol. 2013;27:205-23.
8. Luchini C, Capelli P, Fassan M, Simbolo M, Mafficini A, Pedica F, et al. Next-generation histopathological diagnosis: a lesson from a hepatic carcinosarcoma. J Clin Oncol. 2013 (in press).
9. Scarpa A, Sikora K, Fassan M, Rachiglio AM, Cappellesso R, Antonello D, et al. Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS ONE 2013;8:e80478.
10. Rugge M, de Boni M, Pennelli G, de Bona M, Giacomelli L, Fassan M, et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinicopathological follow-up study. Aliment Pharmacol Ther. 2010;31:1104-11.
11. Lauwers GY, Carneiro F, Graham DY, et al. Gastric carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system, vol 98. 4th ed. Lyon: International Agency for Research on Cancer (IARC). 2010; p 48-68.
12. Simbolo M, Gottardi M, Corbo V, Fassan M, Mafficini A, Malpeli G, et al. A standardized workflow for the qualification of DNA preparations. PLoS ONE. 2013;8:e62692.
13. Zamo A, Bertolaso A, van Raaij AW, Mancini F, Scardoni M, Montresor M, et al. Application of microfluidic technology to the BIOMED-2 protocol for detection of B-cell clonality. J Mol Diagn. 2012;14:30-7.
14. Manfé V, Biskup E, Johansen P, Kamstrup MR, Krejsgaard TF, Morling N, et al. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53. J Invest Dermatol. 2012;132:1487-96.
15. Bria E, De Manzoni G, Beghelli S, Tomezzoli A, Barbi S, Di Gregorio C, et al. A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. Ann Oncol. 2013;24:693-701.
16. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. 2012;44:570-4.
17. Cassaro M, Rugge M, Tieppo C, Giacomelli L, Velo D, Nitti D, et al. Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype. J Clin Pathol. 2007;60:615-21. (Pubitemid 46975214)
18. Dong B, Xie YQ, Chen K, Wang T, Tang W, You WC, et al. Differences in biological features of gastric dysplasia, indefinite dysplasia, reactive hyperplasia and discriminant analysis of these lesions. World J Gastroenterol. 2005;11:3595-600. (Pubitemid 40903521)
19. Anagnostopoulos GK, Stefanou D, Arkoumani E, Karagiannis J, Paraskeva K, Chalkley L, Habilomati E, et al. Immunohistochemical expression of cell-cycle proteins in gastric precancerous lesions. J Gastroenterol Hepatol. 2008;23:626-31. (Pubitemid 351501147)
20. Fassan M, Mastracci L, Grillo F, Zagonel V, Bruno S, Battaglia G, et al. Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology (Oxf). 2012;61:769-76.
21. Lee J, van Hummelen P, Go C, Palescandolo E, Jang J, Park HY, et al. High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS ONE. 2012;7:e38892.
22. Yajima H, Isomoto H, Nishioka H, Yamaguchi N, Ohnita K, Ichikawa T, et al. Novel serine/threonine kinase 11 gene mutations in Peutz-Jeghers syndrome patients and endoscopic management. World J Gastrointest Endosc. 2013;5:102-10.
23. Kim JW, Im SA, Kim MA, Cho HJ, Lee DW, Lee KH, et al. Ataxia-telangiectasia mutated (ATM) protein expression with microsatellite instability in gastric cancer as prognostic marker. Int J Cancer 2014:134;72-80.
24. Barbi S, Cataldo I, De Manzoni G, Bersani S, Lamba S, Mattuzzi S, et al. The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res. 2010;29:32.
25. Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013;32:3091-100.